May 13, 2008First quarter 2008 results Operating results for the Solvay Group in the 1st quarter of 2008 : -8% compared to the high level of the 1st quarter of 2007. An increase of 12% compared to the 4th quarter of 2007. Net income of the Group (eur 220 million) up by 1%.
October 26, 2007Nine months 2007 results Solvay’s operating results (EUR 925 million) 5% above the excellent results from the first 9 months of 2006 (+8% in the 3rd quarter)
July 27, 2007First half 2007 results Solvay’s operating results of EUR 616 million for the 1st half of 2007, exceeding the excellent results for the 1st half of 2006
October 27, 2006Nine months 2006 results Excellent operating results from the Solvay Group for the first nine months of 2006, reflecting further sustained growth in the third quarter
October 12, 2006
Solvay Pharmaceuticals and Wyeth announce submission of new drug application for Bifeprunox to treat schizophrenia Solvay Pharmaceuticals, Inc. and Wyeth Pharmaceuticals, a division of Wyeth (NYSE:WYE), announce today that a New Drug Application (NDA) was submitted to the U.S. Food and Drug Administration (FDA) for bifeprunox, an investigational, new generation atypical antipsychotic for treatment and maintenance of stability of schizophrenic patients.
July 28, 2006First half 2006 results Excellent operating results for the Solvay group in the 1st half of 2006, again reflecting strong growth
February 16, 20062005 Results New records for Solvay in 2005, after excellent results in 2004
February 02, 2006Press release Following its acquisition of Fournier Pharma in July 2005, Solvay Pharmaceuticals has begun a process of reflection in order to integrate the two companies
September 26, 2005Solvay and Pronova Biocare sign license agreement for Omacor® SOLVAY PHARMACEUTICALS and PRONOVA BIOCARE (Norway) announce today the signing of an additional license and supply agreement for OMACOR®, a product indicated for the secondary prevention after myocardial infarction (MI) and hypertriglyceridemia.
August 02, 2005Solvay and Berna Biotech sign a license agreement for Aerugen® Solvay Pharmaceuticals and Berna Biotech Ltd announce today that they have signed a commercialization and license agreement for Aerugen®, a vaccine for the prevention of Pseudomonas aeruginosa (PA) infection in Cystic Fibrosis (CF) patients. The agreement complements Solvay Pharmaceuticals’ CF product portfolio. Aerugen® has a particularly high value in the treatment of CF patients, for whom PA infection is a major cause of death.
August 02, 2005Solvay and Berna Biotech sign a license agreement for Aerugen® Solvay Pharmaceuticals and Berna Biotech Ltd announce today that they have signed a commercialization and license agreement for Aerugen®, a vaccine for the prevention of Pseudomonas aeruginosa (PA) infection in Cystic Fibrosis (CF) patients.
July 28, 2005Solvay completes acquisition of Fournier Pharma Solvay announced today that it has completed the acquisition of 100% of Fournier Pharma, following the successful completion of social and regulatory procedures worldwide.
July 12, 2005Solvay finalizes agreement to buy Fournier Pharma Solvay announced today that it has signed a final purchase agreement with the shareholders of Fournier Pharma for the acquisition of 100% of the company.
June 30, 2005MHRA requests further information on Cilansetron MHRA requests further information on Cilansetron, Solvay ‘s proposed treatment for irritable bowel syndrome with diarrhea predominance (D-IBS)
January 21, 2005Solvay Pharmaceuticals completes acquisition of Neopharma in Sweden SOLVAY PHARMACEUTICALS announces the successful completion of the acquisition of NEOPHARMA AB, a company based in Uppsala, Sweden, as shareholders representing 100% of the company’s capital accepted the friendly takeover bid launched by Solvay last December.
